2Andrus MR,Pharm D. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature Pharma cotherapy,2004,24(2) :285.
3The SPARCL Investigators The stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerehrovasc Dis,2006, 21 (Suppl 4) :1.
4Reeves MJ,Gargano JW, Luo Z, et al. Effect of pretreatment with statins on ischemie stroke outcomes. Stroke,2008,39(6):1779.
5Bifulco M, Malfitano AM, Marasco G. Potential therapeutic role of statins in neurological disorders. Expert Rev Neurother, 2008,8 (5) :827.
6Sturgeon JD, Folsom AR, Longstreth WT Jr, et al. Risk factors for intraeerebral hemorrhage in a pooled prospective study. Stroke, 2007, 38(10) :2718.
7Vergouwen MD, de Haan RJ, Vermeulen M, et aI. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke, 2008,39 (2) : 497.
8Kadikoylu G, Yukselen V, Yavasoglu I, et al. Hemostatie effects of atorvastatin versus simvastatin. Ann Pharmacother,2003,37(4) :478.
9Gonzalez-Ponte ML, Gonzdlez-Rulz M, Duvos E,et ai. Atorvastatin- induced severe thrombocytopenia. Lancet,1998,352(9136) :1284.
10Pattis P, Wiedermann CJ. Ezetimibe-associated immune thrombocytopenia. Ann Pharmacother, 2008,42(3):430.
3Michael OC. Anticoagulation in the ambulatory patient:Basic prin ciples and current concepts in warfarin therapy[J]. Topics in Geri atric Rehabilitation, 2001,17(2) : 18 - 37.
4Booth SL,Centurelli MA. Vitamin K:A practical guide to the diet ary management of patients on warfarin[J]. Nutrition Reviews 1999,57(1):288 296.
